Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 2, 2004, Pages 341-347

  King, Christopher R ^a   Presti Jr , Joseph C ^a   Gill, Harcharan ^a   Brooks, James ^a   Hancock, Steven L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen suppression; Postoperative radiotherapy; Prostate cancer; Radical prostatectomy

Indexed keywords

BIOCHEMISTRY; HAZARDS; HORMONES; ONCOLOGY; PATIENT MONITORING; SURGERY;

ANDROGEN; RADICAL; SUPPRESSION;

RADIOTHERAPY;

ANDROGEN; GONADORELIN AGONIST; HORMONE ANTAGONIST; NONSTEROIDAL ANTIANDROGEN AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; FOLLOW UP; HORMONAL REGULATION; HORMONE ACTION; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; TOTAL ANDROGEN SUPPRESSION; TREATMENT FAILURE; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; STATISTICS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 2442621446     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.015     Document Type: Article

References (34)

1. Katz M.S., Zelefsky M.J., Venkatraman E.S., et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 21:2003;483-489
2. Chawla A.K., Thakral H.K., Zietman A.L., et al. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma Analysis of efficacy and prognostic factors. Urology. 59:2002;726-731
3. Kalapurakal J.A., Huang C.F., Neriamparampil M.M., et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys. 54:2002;1047-1054
4. Leventis A.K., Shariat S.F., Kattan M.W., et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 19:2001;1030-1039
5. Catton C., Gospodarowicz M., Warde P., et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 59:2001;51-60
6. Anscher M.S., Clough R., Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy The first 10 years. Int J Radiat Oncol Biol Phys. 48:2000;369-375
7. Pisansky T.M., Kozelsky T.F., Myers R.P., et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 163:2000;845-850
8. Peschel R.E., Robnett T.J., Hesse D., et al. PSA based review of adjuvant and salvage radiation therapy vs observation in postoperative prostate cancer patients. Int J Cancer. 90:2000;29-36
9. Leibovich B.C., Engen D.E., Patterson D.E., et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 163:2000;1178-1182
10. Nudell D.M., Grossfeld G.D., Weinberg V.K., et al. Radiotherapy after radical prostatectomy Treatment outcomes and failure patterns. Urology. 54:1999;1049-1057
11. Vicini F.A., Ziaja E.L., Kestin L.L., et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 54:1999;111-117
12. Egawa S., Ohori M., Iwamura M., et al. Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy. Br J Urol. 84:1999;815-820
13. Valicenti R.K., Gomella L.G., Ismail M., et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer The importance of radiation dose. Urology. 52:1998;1034-1040
14. Caddedu J.A., Partin A.W., DeWeese T.L., et al. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 159:1998;173-178
15. Do T., Parker R.G., Do C., et al. Salvage radiotherapy for biochemical and clinical features following radical prostatectomy. Cancer J Sci Am. 4:1998;324-330
16. Rogers R., Grossfeld G.D., Roach M. III, et al. Radiation therapy for the management of biopsy-proven local recurrence after radical prostatectomy. J Urol. 160:1998;1748-1753
17. Garg M.K., Tekyi-Mensah S., Bolton S., et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology. 51:1998;998-1002
18. Eulau S.M., Tate D.J., Stamey T.A., et al. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;735-740
19. Morris M.M., Dallow K.C., Zietman A.L., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 38:1997;731-736
20. Crane C.H., Rich T.A., Read P.W., et al. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys. 39:1997;681-686
21. van der Kooy M., Pisansky T.M., Cha S.S., et al. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology. 49:1997;65-70
22. Schild S.E., Buskirk S.J., Wong W.W., et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol. 156:1996;1725-1729
23. Syndikus I., Pickles T., Kostashuk E., et al. Postoperative radiotherapy for stage pT3 carcinoma of the prostate Improved local control. J Urol. 155:1996;1983-1986
24. Forman J.D., Duclos M., Shamsa F., et al. Predicting the need for adjuvant systemic therapy in patients receiving postprostatectomy irradiation. Urology. 47:1996;382-386
25. Medini E., Medini I., Reddy P.K., et al. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen after radical prostatectomy. Cancer. 78:1996;1254-1259
26. McCarthy J.F., Catalona W.J., Hudson M.A. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy Early versus delayed treatment. J Urol. 151:1994;1575-1578
27. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy report of RTOG 85-31. J Clin Oncol. 15:1997;1013-1021
28. Bolla M., Gonsalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300
29. Hanks G.E., Lu J., Machtay M., et al. RTOG 92-02 A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy for locally advanced carcinoma of the prostate. [Abstract] Int J Radiat Oncol Biol Phys. 48:2000;112
30. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 50:2001;1243-1252
31. Roach M. 3rd, DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression Radiation Therapy Oncology Group 9413. J Clin Oncol. 21:2003;1904-1911
32. Corn B.W., Winter K., Pilepich M.V. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Urology. 54:1999;495-502
33. Tiguert R., Rigaud J., Lacombe L., et al. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol. 170:2003;447-450
34. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597